Literature DB >> 18062798

Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells.

L Airas1, M Saraste, S Rinta, I Elovaara, Y-H Huang, H Wiendl.   

Abstract

Multiple sclerosis (MS) ameliorates typically during pregnancy but after the delivery the relapse rate often increases. Our study was conducted to understand the immunoregulatory mechanisms accompanying this phenomenon. MS patients were followed-up prospectively during pregnancy and 6 months postpartum, with immunological characterization of the peripheral blood. Groups of age- and parity-matched healthy pregnant women, and age- and sex-matched non-pregnant women and non-pregnant MS patients were studied as controls. In our patient cohort, the annualized relapse rate was 1.0 +/- 1.0 relapses/woman/year (mean +/- standard deviation) during the year before pregnancy, but dropped to 0.2 +/- 0.9 during the third trimester (P = 0.02). After the delivery the relapse rate increased again to 1.4 +/- 1.9 (1-3 months postpartum versus third trimester P = 0.003). While percentages of peripheral blood CD3, CD4, CD8 and CD19 immune cell subsets were unchanged over the observation period, reduced disease activity during the last trimester was associated with a significant increase in the percentage of circulating CD56(bright) natural killer (NK) cells. Simultaneously, the proportion of circulating CD56(dim) NK cells was clearly reduced. No alteration was noted in CD4+ CD25(high) forkhead box P3+ regulatory T cells. Production of interferon-gamma by peripheral blood lymphocytes was down-regulated significantly during pregnancy in comparison to the postpartum period, resulting in an increased T helper type 2 (Th2) : Th1 ratio during pregnancy. In conclusion, pregnant state in MS patients is characterized by an increase in the percentage of CD56(bright) NK cells and by enhanced Th2 type cytokine secretion. Our findings suggest a potential role for CD56(bright) regulatory NK cells in the control of autoimmune inflammation during pregnancy in MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18062798      PMCID: PMC2276950          DOI: 10.1111/j.1365-2249.2007.03555.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

Review 1.  Tolerance signaling molecules.

Authors:  David A Clark
Journal:  Chem Immunol Allergy       Date:  2005

2.  Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis.

Authors:  Wen Xu; Gyorgy Fazekas; Hideo Hara; Takeshi Tabira
Journal:  J Neuroimmunol       Date:  2005-06       Impact factor: 3.478

3.  The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system.

Authors:  DeRen Huang; Fu-Dong Shi; Steffen Jung; Gary C Pien; Jintang Wang; Thais P Salazar-Mather; Toby T He; Jennifer T Weaver; Hans-Gustaf Ljunggren; Christine A Biron; Dan R Littman; Richard M Ransohoff
Journal:  FASEB J       Date:  2006-05       Impact factor: 5.191

4.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Authors:  Bibiana Bielekova; Marta Catalfamo; Susan Reichert-Scrivner; Amy Packer; Magdalena Cerna; Thomas A Waldmann; Henry McFarland; Pierre A Henkart; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

5.  A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127.

Authors:  Christian A J Vosshenrich; Marcos E García-Ojeda; Sandrine I Samson-Villéger; Valerie Pasqualetto; Laurence Enault; Odile Richard-Le Goff; Erwan Corcuff; Delphine Guy-Grand; Benedita Rocha; Ana Cumano; Lars Rogge; Sophie Ezine; James P Di Santo
Journal:  Nat Immunol       Date:  2006-10-01       Impact factor: 25.606

6.  Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients.

Authors:  Carmen Infante-Duarte; Alexandra Weber; Jörn Krätzschmar; Timour Prozorovski; Susan Pikol; Isabell Hamann; Judith Bellmann-Strobl; Orhan Aktas; Jan Dörr; Jens Wuerfel; Claus-Steffen Stürzebecher; Frauke Zipp
Journal:  FASEB J       Date:  2005-09-06       Impact factor: 5.191

7.  Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein.

Authors:  Michal Irony-Tur-Sinai; Nikolaos Grigoriadis; Athanasios Lourbopoulos; Florence Pinto-Maaravi; Oded Abramsky; Talma Brenner
Journal:  Exp Neurol       Date:  2006-01-19       Impact factor: 5.330

8.  Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients.

Authors:  U Feger; C Luther; S Poeschel; A Melms; E Tolosa; H Wiendl
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

Review 9.  Evidence that pregnancy specific glycoproteins regulate T-Cell function and inflammatory autoimmune disease during pregnancy.

Authors:  Bruce F Bebo; Gabriela S Dveksler
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

10.  Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta.

Authors:  M Saraste; H Irjala; L Airas
Journal:  Neurol Sci       Date:  2007-06-30       Impact factor: 3.307

View more
  32 in total

Review 1.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

Review 2.  Janus head: the dual role of HLA-G in CNS immunity.

Authors:  Yu-Hwa Huang; Laura Airas; Nicholas Schwab; Heinz Wiendl
Journal:  Cell Mol Life Sci       Date:  2010-11-18       Impact factor: 9.261

3.  Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE.

Authors:  Eduardo Huarte; Agnieszka Rynda-Apple; Carol Riccardi; Jerod A Skyberg; Sarah Golden; Maryclare F Rollins; Andrew G Ramstead; Larissa O Jackiw; Massimo Maddaloni; David W Pascual
Journal:  J Autoimmun       Date:  2011-10-22       Impact factor: 7.094

Review 4.  Role of the innate immune system in the pathogenesis of multiple sclerosis.

Authors:  Roopali Gandhi; Alice Laroni; Howard L Weiner
Journal:  J Neuroimmunol       Date:  2010-04-15       Impact factor: 3.478

5.  CX3CR1-dependent recruitment of mature NK cells into the central nervous system contributes to control autoimmune neuroinflammation.

Authors:  Laura Hertwig; Isabell Hamann; Silvina Romero-Suarez; Jason M Millward; Rebekka Pietrek; Coralie Chanvillard; Hanna Stuis; Karolin Pollok; Richard M Ransohoff; Astrid E Cardona; Carmen Infante-Duarte
Journal:  Eur J Immunol       Date:  2016-07-14       Impact factor: 5.532

Review 6.  Sex-related factors in multiple sclerosis susceptibility and progression.

Authors:  Rhonda R Voskuhl; Stefan M Gold
Journal:  Nat Rev Neurol       Date:  2012-03-27       Impact factor: 42.937

Review 7.  Caring for Women with Multiple Sclerosis Across the Lifespan.

Authors:  Kelsey Rankin; Riley Bove
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

8.  Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells.

Authors:  Philip L De Jager; Elizabeth Rossin; Saumyadipta Pyne; Pablo Tamayo; Linda Ottoboni; Vissia Viglietta; Mira Weiner; Dulce Soler; Elena Izmailova; Lauren Faron-Yowe; Carmeline O'Brien; Sam Freeman; Susana Granados; Alex Parker; Ronenn Roubenoff; Jill P Mesirov; Samia J Khoury; David A Hafler; Howard L Weiner
Journal:  Brain       Date:  2008-06-21       Impact factor: 13.501

9.  GPR30, but not estrogen receptor-alpha, is crucial in the treatment of experimental autoimmune encephalomyelitis by oral ethinyl estradiol.

Authors:  Melissa A Yates; Yuexin Li; Peter J Chlebeck; Halina Offner
Journal:  BMC Immunol       Date:  2010-04-19       Impact factor: 3.615

Review 10.  Pregnancy and multiple sclerosis: from molecular mechanisms to clinical application.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  Semin Immunopathol       Date:  2016-08-08       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.